You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Baseline demographic and clinical characteristics of treated patients

From: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

Characteristic N + S (N = 33) N + P (N = 20)
Age, years
 Median (range) 57.0 (38–75) 56.0 (40–72)
Age <65 years, n (%) 24 (72.7) 17 (85.0)
Sex, n (%)
 Male 26 (78.8) 18 (90.0)
 Female 7 (21.2) 2 (10.0)
Race, n (%)
 Caucasian 28 (84.8) 18 (90.0)
 Asian 1 (3.0) 0
 Black/African American 2 (6.1) 1 (5.0)
 Other 2 (6.1) 1 (5.0)
Ethnicity, n (%)
 Hispanic/Latino 2 (6.1) 0
 Not Hispanic/Latino 29 (87.9) 18 (90.0)
 Not reported 2 (6.1) 2 (10.0)
MSKCC risk category, n (%)
 Favorable 16 (48.5) 4 (20.0)
 Intermediate 16 (48.5) 14 (70.0)
 Poor 1 (3.0) 2 (10.0)
Prior surgery, n (%) 33 (100.0) 20 (100.0)
Prior radiotherapy, n (%) 5 (15.2) 10 (50.0)
Prior systemic therapy, n (%) 14 (42.4) 20 (100.0)
 VEGFR inhibitor 5 (15.2) 17 (85.0)
 Other antiangiogenic 7 (21.2) 17 (85.0)
 Cytokine 9 (27.3) 10 (50.0)
 mTOR inhibitor 0 3 (15.0)
 Other 3 (9.1) 4 (20.0)
No. of prior therapies, n (%)
 0 19 (57.6) 0
 1 14 (42.4) 14 (70.0)
 2 0 4 (20.0)
 3 0 1 (5.0)
  ≥4 0 1 (5.0)
Treatment setting, a n (%)
 Adjuvant 3 (9.1) 4 (20.0)
 Metastatic 0 2 (10.0)
 Neoadjuvant 11 (33.3) 16 (80.0)
  1. aMore than one setting per patient may be reflected in the frequency